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Objectives The goal of this study was to determine whether subclinical thyroid dysfunction was associated with incident
heart failure (HF) and echocardiogram abnormalities.
Background Subclinical hypothyroidism and hyperthyroidism have been associated with cardiac dysfunction. However, long-
term data on the risk of HF are limited.
Methods We studied 3,044 adults 65 years of age who initially were free of HF in the Cardiovascular Health Study. We
compared adjudicated HF events over a mean 12-year follow-up and changes in cardiac function over the course
of 5 years among euthyroid participants, those with subclinical hypothyroidism (subdivided by thyroid-stimulating
hormone [TSH] levels: 4.5 to 9.9, 10.0 mU/l), and those with subclinical hyperthyroidism.
Results Over the course of 12 years, 736 participants developed HF events. Participants with TSH 10.0 mU/l had a greater
incidence of HF compared with euthyroid participants (41.7 vs. 22.9 per 1,000 person years, p 0.01; adjusted haz-
ard ratio: 1.88; 95% confidence interval: 1.05 to 3.34). Baseline peak E velocity, which is an echocardiographic mea-
surement of diastolic function associated with incident HF in the CHS cohort, was greater in those patients with TSH
10.0 mU/l compared with euthyroid participants (0.80 m/s vs. 0.72 m/s, p 0.002). Over the course of 5 years,
left ventricular mass increased among those with TSH10.0 mU/l, but other echocardiographic measurements were
unchanged. Those patients with TSH 4.5 to 9.9 mU/l or with subclinical hyperthyroidism had no increase in risk of HF.
Conclusions Compared with euthyroid older adults, those adults with TSH 10.0 mU/l have a moderately increased risk of
HF and alterations in cardiac function but not older adults with TSH 10.0 mU/l. Clinical trials should assess
whether the risk of HF might be ameliorated by thyroxine replacement in individuals with TSH 10.0
mU/l. (J Am Coll Cardiol 2008;52:1152–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.009(
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September 30, 2008:1152–9 Subclinical Thyroid Dysfunction and HF2,3). Whereas it is generally accepted to treat the abnormal
ree thyroxine levels of overt thyroid dysfunction, the
ndications and threshold TSH for treatment of subclinical
ypothyroidism and subclinical hyperthyroidism are areas of
linical controversy (1,3,4) because current evidence about
he risks is limited (1,3).
On the basis of the known effects of thyroid hormone on
he heart, it is reasonable to expect adverse cardiac effects in
ubclinical thyroid dysfunction (5). Subclinical thyroid dis-
ase has been associated with systolic and diastolic cardiac
ysfunction, and small studies have shown that thyroxine
eplacement improved measurements of cardiac function in
ubjects with subclinical hypothyroidism (6,7). However,
he clinical importance of these effects is unclear (3,8). Data
n cardiovascular risks are conflicting (9–11), and no
andomized clinical trials (RCTs) have assessed the impact
f thyroxine replacement on clinical cardiac end points (3).
nly one study has examined the relationship between
ubclinical thyroid dysfunction and heart failure (HF)
vents. In a population-based study of adults ages 70 to 79
ears, participants with TSH 7.0 mU/l had a more than
-fold greater risk of HF events compared with euthyroid
ubjects (10), but echocardiography was not performed. No
tudy has directly addressed the relationship between sub-
linical hyperthyroidism and HF events.
As the number of hospitalizations for HF has greatly
ncreased (12), examining a common and easily treatable
otential risk factor for HF is warranted. To determine
hether subclinical thyroid dysfunction was associated with
F and cardiac dysfunction, we examined a large cohort
tudy of community-dwelling older adults.
ethods
tudy population. Participants were part of the Cardio-
ascular Health Study (CHS), a population-based, longitu-
inal study of risk factors for the development of cardiovas-
ular disease (CVD) in 5,888 adults who were 65 years of
ge (13). Enrollment of an original cohort of 5,201 adults
ccurred in 1989 to 1990, and an additional cohort of 687,
redominantly comprising African-American subjects, was
nrolled in 1992 to 1993. Eligible individuals were identi-
ed from an age- and gender-stratified random sample of
he Medicare-eligible adults in 4 U.S. communities. Details
f the eligibility criteria have been previously described (9).
ll participants gave written informed consent; the institu-
ional review boards at study sites approved the protocol.
Fasting TSH was measured at baseline in a subsample
n  3,678) of CHS participants, who were selected
ccording to availability of stored serum for analysis. Be-
ause our primary study question pertained to unrecognized
hyroid function abnormalities, participants taking thyroid
ormone preparations at baseline (n  339) or other
edications that could affect thyroid testing, including
ntithyroid drugs (n  1), corticosteroids (n  77), and
miodarone (n  2), were excluded. We also excluded tarticipants with known HF at
aseline (n  144) to examine
ncident HF.
easurements. THYROID HOR-
ONES. Serum TSH and FT4
oncentrations were assayed, as
reviously described (9), with
T4 (normal range: 0.7 to 1.7
g/dl [9 to 22 pmol/l]) measured
n individuals with TSH 0.10
r 4.50 mU/l for the 95% of
amples with sufficient serum for
his additional test. Compared
ith participants who did not
eceive thyroid function testing
n  1,523), participants with
hyroid function testing were less
ikely to be men (38% vs. 55%, p  0.001) and to have
revalent CVD (22% vs. 26%, p  0.002), but mean ages,
ace proportions, thyroxine use, and prevalent HF were
imilar.
Study participants were classified into 3 groups based on
heir thyroid function tests (9): 1) subclinical hyperthyroidism:
SH 0.10 and 0.45 mU/l (3) (n  38), or 0.10 mU/l
ith a normal FT4 (n  6); 2) euthyroidism: normal TSH
0.45 to 4.50 mU/l; n  2,526); or 3) subclinical hypo-
hyroidism: TSH 4.50 and 20.0 mU/l with a normal
T4 (n  474). On the basis of the definitions used by
he U.S. Preventive Services Task Force (1) and on expert
onsensus (3), subclinical hypothyroidism was subclassi-
ed according to the following TSH levels, 4.5 to 9.9
U/l (n  428), and 10.0 mU/l (marked elevation, n 
6), because of possible greater risks above this cut-off. In
dditional analyses, mild subclinical hypothyroidism was
urther subclassified between those with TSH 4.5 to 6.9
U/l (mild elevation, n  337) and 7.0 to 9.9 mU/l
moderate elevation, n  91), based upon U.S. Preventive
ervices Task Force definitions (1).
Participants whose testing suggested nonthyroidal illness
low TSH and FT4, n  2), TSH 4.50 mU/l and a
issing FT4 (n  21), and overt thyrotoxicosis (TSH
0.10 mU/l with an increased FT4, n  1) or overt
ypothyroidism (TSH 20.0 or 4.50 mU/l with a FT4
0.70 ng/dl, n  47) were excluded from analyses. The
ample for our analyses was 3,044 patients.
F EVENTS. During the 15-year follow-up, we assessed
ncident HF events among participants free of HF at
aseline. Clinical outcomes were ascertained every 6
onths. Diagnoses have been adjudicated until June 30,
004, based on interview, review of medical records, and
ther support documents without physician knowledge of
hyroid status. Heart failure events were defined on the basis
f diagnosis from a physician and consideration of symp-
Abbreviations
and Acronyms
CHS  Cardiovascular
Health Study
CI  confidence interval
CVD  cardiovascular
disease
FT4  free thyroxine
HF  heart failure
HR  hazard ratio
LV  left ventricular
RCT  randomized
controlled trial
TSH  thyroid-stimulating
hormoneoms, signs, chest radiographs, and treatment of HF (cur-
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Subclinical Thyroid Dysfunction and HF September 30, 2008:1152–9ent prescription for a diuretic agent and digitalis or a
asodilator) (14,15).
CHOCARDIOGRAPHY. As previously described (16), echo-
ardiographic images were obtained in 1989 to 1990 and 1994
o 1995, with the use of a standardized protocol with core
eading centers. All following measurements were examined
ithout knowledge of the participant’s thyroid status. Left
entricular (LV) mass and fractional shortening at the midwall,
quantitative measurement of global chamber function, were
alculated as reported previously (17). Qualitative assessment
f LV ejection fraction was classified as normal, borderline,
r abnormal, approximately corresponding to values 55%,
45%, and 45%, respectively (17). Agreement between
aseline and 5-year follow-up echocardiography core centers
as been previously reported (17). For diastolic function, left
trial size, Doppler peak E and A velocities were measured
18,19). Doppler filling velocities and their ratios, which were
onsistent with impaired relaxation and restrictive filling, were
reviously found in CHS to be predictive of incident HF (14).
total of 896 participants had missing echocardiograms from
994 to 1995 because of death (36%), missed visit (17%), or
ollow-up visit outside the clinics with no echocardiogram
47%). The 576 living participants without follow-up echocar-
iograms were older; more likely to be nonwhite; to smoke;
nd to have diabetes, atrial fibrillation, and subclinical hyper-
hyroidism (2.9% vs. 1.4%); the prevalence of hypertension,
VD, subclinical hypothyroidism, and gender proportions did
ot differ significantly. We based LV ejection fraction mea-
urements at the time of incident HF on data that were
bstracted from reports of echocardiograms performed during
ospitalization for HF, and we classified these measurements
s described in the preceding text.
OVARIATES. We collected self-reported race and smoking
tatus, classified as never, current, or former. Thyroid
edication use was assessed annually via medication bottle
xamination. Physical examination included blood pres-
ure, heart rate, and body mass index. Hypertension was
efined as self-report and the use of antihypertensive
edications or as a blood pressure 140/90 mm Hg.
iabetes was defined as a fasting glucose 126 mg/dl
7.0 mmol/l) or the use of hypoglycemic medication.
trial fibrillation at baseline was self-reported or determined
n electrocardiogram or with a Holter monitor (9). For
revalent HF at baseline, self-reports were confirmed by
hysical examination or, if necessary, by a validation protocol
hat included surveys of treating physicians or review of
edical records (20). Prevalent CVD (defined as coronary
eart disease, stroke, or transient ischemic attack) was based
n patient self-report, verification of the patient’s medical
ecord, and patient’s use of selected drugs.
tatistical analysis. We calculated HF incidence per 1,000
erson-years of follow-up and used log-rank tests to com-
are Kaplan-Meier estimates of HF incidence across the 4
hyroid groups. We used Cox proportional hazards survival
odels to examine associations between the 4 groups and rF. The multivariate models adjusted for known clinical
isk factors of HF in older adults (12,15,21,22) that might
e potential confounders in the relationship between sub-
linical thyroid disease and HF. To check the sensitivity of
ur results to the selection of covariates, we assessed models
hat excluded potential confounders with p  0.2 after
djustment and obtained similar results. We hypothesized
ome interactions a priori: the relationship between subclin-
cal thyroid disease and HF might differ by gender, preva-
ent CVD, or thyroxine use during follow-up. As detailed
reviously (9), we first examined models in which follow-up
as censored at the time of first thyroxine use as the main
nalysis. Because of interaction with thyroxine use, we also
sed models in which baseline hazard was stratified by
hyroxine use during follow-up as a time-dependent covari-
te, and participants changed stratum when thyroxine use
as initiated.
We graphically examined smooth estimates of hazard
unction for HF against TSH to examine cutpoints at which
F risk might be increased, as well as tabulation of event
ates within smaller TSH intervals, and used Schoenfeld
esiduals to check proportional hazards assumption for
hyroid status and for covariates included in the multivariate
odels. We used models with baseline hazard jointly
tratified by 4 variables (prevalent atrial fibrillation, CVD,
iabetes, and hypertension) that did not meet this assump-
ion (23). We also categorized age, the only continuous
ovariate that did not meet the assumption of log-linearity.
esults were reported as hazard ratios (HRs) with 95%
onfidence intervals (CIs).
Among participants with echocardiographic data, multi-
le linear regression was used to assess baseline differences
nd changes over time in echocardiographic measurements
cross thyroid groups, after adjustment for age and gender,
imilar to previous analyses of echocardiograms in CHS
14). We conducted analyses using Stata 9.2 (Stata Corp.,
ollege Station, Texas).
esults
aseline characteristics. The mean age was 72.6 years;
0% were women (Table 1). Mild subclinical hypothyroidism
TSH 4.5 to 9.9 mU/l) was present in 428 (14.5%)
articipants, severe subclinical hypothryoidism (TSH 10.0
o 19.9 mU/l) in 46 (1.5%), and subclinical hyperthyroidism
n 44 (1.4%). Subclinical hypothyroidism was more com-
on in women and was associated with lower systolic blood
ressure. Subclinical hyperthyroidism was associated with
reater body mass index and lower low-density lipoprotein
holesterol.
aseline echocardiographic data. Most echocardiographic
easurements at baseline did not differ significantly by thyroid
tatus (Table 2). Participants with TSH 10.0 mU/l had a
reater peak E velocity (0.80 m/s vs. 0.72 m/s, p 0.002), and
his difference persisted after adjustment for age, gender, heart
ate, and systolic blood pressure. Peak E velocity was associated
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September 30, 2008:1152–9 Subclinical Thyroid Dysfunction and HFith incident HF in the overall study sample (HR: 1.14 for
ach 0.1 m/s increment; 95% CI: 1.09 to 1.18; p 0.001) and
n those with TSH 10.0 mU/l (HR: 1.45; 95% CI: 1.20 to
.76; p  0.001) after adjustment for age, gender, and systolic
lood pressure. Compared with euthyroidism, subclinical hy-
erthyroidism was associated with larger left atrial size, greater
roportions with early/late transmitral peak flow velocity ratio
0.7, and increased heart rate (Table 2), differences that
ersisted after excluding those with atrial fibrillation.
isk of HF events. Over a median (interquartile range)
ollow-up of 12 years (7.0 to 14.4 years), 736 (24%) of 3,044
articipants developed HF events. Among the 474 partici-
ants with sublinical hypothyroidism, 109 received thyrox-
ne replacement during follow-up, with 28 reporting inter-
ittent use. Among the 46 participants with TSH 10.0
U/l, 22 received thyroxine during follow-up (7 intermit-
ent use). In the analysis censoring follow-up at first
hyroxine use, participants with TSH 10.0 mU/l had a
reater incidence of HF compared with euthyroid partici-
aseline Characteristics of Study Population According to Thyroid
Table 1 Baseline Characteristics of Study Population Accordin
TSH Categories, mU/l
Total
(n  3,044)
Subclinical
<
(n 
TSH, mU/l 2.88 (2.14) 0.24
Free thyroxine, ng/dl 1.27
Age, yrs 72.6 (5.5) 73.8
Female, n (%) 1,826 (60.0) 29
White race, n (%) 2,867 (94.2) 42
Smoking status, n (%)
Current 326 (10.7) 8
Former 1,236 (40.6) 16
Never 1,479 (48.7) 20
Alcohol, drinks/week, n (%)
1 2,084 (68.6) 34
1–6 510 (16.8) 5
7 443 (14.6) 5
Diabetes mellitus, n (%) 405 (13.3) 9
Hypertension, n (%) 1,219 (40.2) 18
Prevalent CVD, n (%) 595 (19.6) 9
Prevalent atrial fibrillation, n (%) 59 (1.9) 1
Body mass index, kg/m2 26.2 (4.4) 27.6
Systolic blood pressure, mm Hg 135.6 (20.9) 140.4
Diastolic blood pressure, mm Hg 69.9 (11.0) 70.6
Lipid values, mg/dl
Total cholesterol 213 (39) 203
LDL cholesterol 131 (35) 120
HDL cholesterol 55 (16) 53
Triglycerides 141 (74) 140
Fasting glucose, mg/dl 108 (32) 110
Creatinine, mg/dl 1.04 (0.32) 0.97
Lipid-lowering medication, n (%) 154 (5.1) 2
alues aremean (SD) or n (%). SI conversions: to convert free thyroxine to pmol/l, multiply by 12.87;
ercentages may not sum to 100 because of rounding, and some numbers may not add to the tota
values are based on chi-square tests and t tests, as appropriate.
CVD  prevalent clinical cardiovascular disease defined as prevalent coronary heart disea
hyroid-stimulating hormone.ants (41.7 vs. 22.9 per 1,000 person-years, p  0.01), but The rates were similar for those with subclinical hyperthy-
oidism or TSH 4.5 to 9.9 mU/l (Fig. 1). In multivariate
nalysis censoring at first thyroxine use, the risk of HF was
ncreased among those with TSH 10.0 mU/l (HR: 1.88;
5% CI: 1.05 to 3.34) (Table 3, model 1). Multivariate
odel omitting lipids yielded similar results.
The relationship between subclinical hypothyroidsim and
F differed by thyroxine use during follow-up (p 0.02 for
nteraction). In a model (Table 3, model 2) that included all
ollow-up and thyroxine use as a time-dependent covariate,
articipants with TSH10.0 mU/l had an increased risk of
F during periods in which thyroxine use was not reported
ut no increased risk during periods of thyroxine use.
lmost identical results were obtained with the use of a
odel that incorporated the history of thyroxine use as a
ime-dependent covariate (participants classified as user
rom first use) and that allowed for interaction of this
easure with thyroid status (data not shown).
Stratifying sublinical hypothyroidism into those with
s in the Cardiovascular Health Study (n  3,044)
hyroid Status in the Cardiovascular Health Study (n  3,044)
thyroid Euthyroid
0.45–4.5
(n  2,526)
Subclinical Hypothyroid
4.5–9.9
(n  428)
10.0–19.9
(n  46)
) 2.21 (0.99) 6.02 (1.36) 12.9 (2.70)
) 1.01 (0.16) 0.89 (0.15)
72.5 (5.5) 73.0 (5.5) 74.0 (6.2)
) 1,488 (58.9) 281 (65.7)* 28 (60.9)
) 2,373 (93.9) 409 (95.6) 43 (93.5)
) 277 (11.0) 36 (8.4) 5 (10.9)
) 1,039 (41.2) 164 (38.4) 17 (37.0)
) 1,208 (47.9) 227 (53.2) 24 (52.2)
) 1,704 (67.6) 311 (72.8) 35 (76.1)
) 434 (17.2) 67 (15.7) 4 (8.7)
) 382 (15.2) 49 (11.5) 7 (15.2)
) 329 (13.0) 61 (14.3) 6 (13.0)
) 1,029 (40.9) 150 (35.1)† 22 (47.8)
) 489 (19.4) 87 (20.3) 10 (21.7)
49 (1.9) 9 (2.1) 0 (0)
† 26.2 (4.3) 26.4 (4.7) 25.7 (4.7)
) 135.9 (21.1) 133.3 (19.1)† 137.1 (25.7)
) 70.1 (11.2) 69.1 (9.7) 69.0 (12.4)
213 (38) 211 (41) 213 (42)
131 (35) 129 (35) 130 (39)
55 (16) 54 (16) 56 (19)
140 (73) 146 (78) 131 (60)
109 (32) 108 (31) 104 (22)
) 1.04 (0.33) 1.06 (0.26) 1.08 (0.29)
137 (5.4) 14 (3.3) 1 (2.2)
L, and total cholesterol tommol/l, multiply by 0.0259; and glucose tommol/l, multiply by 0.0555.
e of missing information. *p 0.01, †p 0.05, for pairwise comparison with euthyroid category;
erebrovascular disease; HDL  high-density lipoprotein; LDL, low-density lipoprotein; TSH Statu
g to T
Hyper
0.45
44)
(0.13
(0.27
(6.9)
(65.9
(95.5
(18.2
(36.4
(45.5
(77.3
(11.4
(11.4
(20.5
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Subclinical Thyroid Dysfunction and HF September 30, 2008:1152–9ound no significantly increased risk of HF; graphical
xamination of hazard function showed no increased risk
p to approximately 10.0 mU/l. A cubic spline analysis
lso showed the nonlinearity of this relationship. None of
he 6 participants with TSH 0.10 mU/l had HF events.
he relationship between subclinical thyroid disease and
chocardiographic Characteristics at Baseline According to Thyroid
Table 2 Echocardiographic Characteristics at Baseline Accordi
TSH Categories, mU/l
Subclinical H
<0.4
(n 
Systolic function
LV ejection fraction, qualitative assessment (n  3,020), %
Normal (55) 88.1
Borderline (55) 9.5
Abnormal (45) 2.4
LV mass, g (n  2,031) 149
Fractional shortening at the midwall, % (n  2,006) 43.3
Diastolic function
Left atrial dimension, mm (n  2,947) 40.7
Peak E, m/s (n  2,951) 0.72
Peak A, m/s (n  2,951) 0.85
E/A ratio (n  2,951), %§ 0.81 (0.6
0.7: impaired relaxation 35.7
0.7–1.5 59.5
1.5: restrictive filling pattern 4.8
Other measurements
Heart rate, beats/min (n  3,034) 69
alues are mean SD or percentages. E/A ratio was used to categorize impaired relaxation (low E/
as not available were not included in the analysis. *p 0.05, †p 0.01 compared with euthyroid
lling velocities, differences were similar after further adjustment for heart rate and systolic blood p
ransformation of the variable (1/) to normalize the distribution for adjusted comparisons.
E/A ratio  early/late transmitral peak flow velocity ratio; LV  left ventricular; Peak A  D
hyroid-stimulating hormone.
Figure 1 Incident HF Events According to TSH Levels
Participants with TSH 10.0 to 19.9 mU/l who were untreated by thyroxine
replacement (participants censored at the time of first thyroxine use) had a
greater incidence of HF events compared with euthyroid participants (41.7 vs.
22.9 per 1,000 person-years, p  0.01), but rates were similar for those with
subclinical hyperthyroidism or those with TSH between 4.5 and 9.9 mU/l.
HF  heart failure; TSH  thyroid-stimulating hormone.yF did not differ by prevalent CVD or gender (each
nteraction p value 0.20). Excluding 595 participants
ith prevalent CVD yielded similar results, including in
hose with TSH 10.0 mU/l (HR: 2.17; 95% CI: 1.15 to
.07) in multivariate analysis censoring at first thyroxine
se. On the basis of baseline echocardiographic data,
eak E velocity might be a potential mediator of this
elationship; further adjusting Model 1 for peak E
elocity yielded an HR of 1.69 (95% CI: 0.94 to 3.02) for
hose with TSH 10.0 mU/l, showing that this relation-
hip was not fully explained by increased peak E velocity
nd that other factors, including unmeasured echocardio-
raphic parameters, might play a role in this relationship.
chocardiographic changes over time. Repeat echocar-
iograms were obtained in 2,148 participants after 5
ears; those with TSH 10.0 mU/l had a greater increase
n LV mass (21 g vs. 4 g, p  0.04) (Table 4) and a
reater proportion of HF events associated with low
jection fraction than in euthyroid participants (80% vs.
5%, p  0.08). Peak E velocity decreased more in
ubjects with TSH 10.0 mU/l than in euthyroid par-
icipants (0.10 m/s vs. 0.01 m/s, p  0.005), which
ight be related to increase in LV mass over time,
ncreasing impairment of LV relaxation, a plateau effect,
r regression to the mean due to greater baseline values.
Compared with euthyroidism, the presence of subclinical
yperthyroidism was associated with a smaller increase in left
trial size and peak A velocity over time, but cross-sectional
tus
Thyroid Status
yroid Euthyroid
0.45–4.5
(n  2,526)
Subclinical Hypothyroid
4.5–9.9
(n  428)
10.0–19.9
(n  46)
93.4 91.0 93.5
4.5 5.2 6.5
2.2 3.8* 0
149 48 144 45 146 42
42.2 8.1 42.5 7.9 43.1 7.8
38.6 6.6 38.5 6.7 39.5 6.5
0.72 0.18 0.72 0.20 0.80 0.25†‡
0.79 0.22 0.79 0.23 0.83 0.26
) 0.89 (0.74–1.07) 0.90 (0.75–1.08) 0.92 (0.82–1.13)
17.4 16.1 13.0
77.0 78.1 82.6
5.6 5.8 4.4
64 10 65 10 64 7
restrictive patterns (high E/A). For each outcome measure, those for whom the outcome measure
y, after adjustment for age and gender. No significant differences for other comparisons. For mitral
e. ‡p 0.008 according to Kruskal-Wallis test. §Expressed as median (25%–75%), and reciprocal
late diastolic peak filling velocity; Peak E  Doppler early diastolic peak filling velocity; TSH Sta
ng to
yperth
5
44)
58
10.1
6.4*
0.18
0.29
8–0.98
†
11*
A) and
categor
ressurear-5 left atrial sizes and peak A velocities did not differ
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.90). Excluding participants with atrial fibrillation at baseline
r those who developed HF before year-5 examination (n 
37) yielded similar results. For the 499 participants who
eveloped HF after year-5 examination, the time interval 
D between the 5-year echocardiograms and HF was 4.4 
.6 years (3.5  1.9 years for those with TSH 10.0 mU/l).
iscussion
n this large, population-based study of older adults,
ubclinical hypothyroidism was associated with a moder-
ubclinical Thyroid Dysfunction and the Risk of Incident Heart Failu
Table 3 Subclinical Thyroid Dysfunction and the Risk of Inciden
TSH Categories, mU/l
Subclinical Hyperthyro
<0.45
No. at risk 44
No. of events 10
Incidence rate (95% CI) per 1,000 person-
years*
23.9 (12.4–45.9)
Adjusted HR (95% CI)
Model 1‡ 0.94 (0.48–1.83)
Model 2§
No thyroxine use during follow-up
With thyroxine use during follow-up
Participants were censored at the time of first use of thyroxine replacement. Those treated by thyr
ith euthyroid category. No significant differences in HF rates for participants with TSH between 4.5
ender, race, clinical cardiovascular disease at baseline, atrial fibrillation at baseline, alcohol use,
reatinine. Hypertension was defined as blood pressure 140/90 mm Hg or by patient self-rep
onverting enzyme inhibitors, or calcium-channel blockers). Participants were censored at the time
xcluded from the study sample. §Stratified model by periods of use or no use of thyroxine repla
ypothyroidism (p  0.02), and adjusted for the same covariates than in model 1 plus thyroxine u
as initiated. No significant interactions in those with subclinical hyperthyroidism.
CI  confidence interval; HF  heart failure; other abbreviations as in Table 1.
hange in Echocardiographic Characteristics Between Baseline1988 to 1989) n 5-Year Follow-Up (1994 to 1995) According to
Table 4 Change in Echocardiographic Characteristics Between(1988 to 1989) and 5-Year Follow-Up (1994 to 1995)
TSH Categories, mU/l
Subclinica
<
(n
Systolic function
LV mass, g (n  1,191) 
Fractional shortening measured at the midwall, % (n  1,121) 2.
Echocardiograms at 5 yrs
LV ejection fraction, qualitative assessment (n  2,032), %‡
Normal (55)
Borderline (55)
Abnormal (45)
Diastolic function
Left atrial dimension, mm (n  2,046) 0.
Peak E, m/s (n  2,017) 0.0
Peak A, m/s (n  1,965) 0.0
Echocardiograms at the time of incident HF
LV ejection fraction, qualitative assessment (n  185), %
Normal
Borderline
Abnormal
alues are mean SD or percentages. *p 0.05, †p 0.01 compared with euthyroid category, af
lling velocities, differences were similar after further adjustment for heart rate and systolic blood pressu
  increase in the measurement from baseline to 5-year follow-up;   decrease in the measuremetely increased risk of HF among older adults with TSH
10.0 mU/l, which is consistent with another large
ohort study of older individuals (10). The risk of CHF
as not increased among the high proportions of older
dults with TSH levels between 4.5 and 9.9 mU/l or
mong those with TSH 0.45 mU/l. Adverse alterations
n 2 echocardiographic measurements, peak E velocity at
aseline—an echocardiographic measurement of diastolic
unction associated with HF in this cohort sample and
revious CHS analysis (14)—and increase in left ventric-
lar mass over the course of 5 years, also were found
vents (n  3,044)
art Failure Events (n  3,044)
Euthyroid
0.45–4.5
Subclinical Hypothyroid
4.5–9.9 10.0–19.9
2,526 428 46
621 89 16
22.9 (21.1–24.8) 20.5 (16.5–25.5) 41.7 (23.7–73.5)†
1.0 0.92 (0.73–1.17) 1.88 (1.05–3.34)
1.0 0.92 (0.73–1.16) 1.83 (1.05–3.20)
1.0 0.28 (0.11–0.74) 0.50 (0.14–1.74)
eplacement at baseline were excluded from the study sample. †p 0.01 for pairwise comparison
.9 mU/l and those with TSH0.45 mU/l compared with euthyroid participants. ‡Adjusted for age,
g status, diabetes mellitus, hypertension, body mass index, LDL cholesterol, HDL cholesterol, and
ypertension and use of blood pressure medications (e.g., diuretics, beta-blockers, angiotensin-
t use of thyroxine replacement. Those patients treated by thyroxine replacement at baseline were
t during follow-up, because of interaction by thyroxine replacement use in those with subclinical
time-dependent covariate during all follow-up. Participants changed stratum when thyroxine use
roid Status
line
rding to Thyroid Status
rthyroid
)
Euthyroid
0.45–4.5
(n  2,526)
Subclinical Hypothyroid
4.5–9.9
(n  428)
10.0–19.9
(n  46)
4 39 3 29 21 31*
.2 0.3 9.6 1.3 8.6 1.4 10.7
89.8 91.4 90.0
7.2 6.5 6.7
3.0 2.2 3.3
2* 1.7 6.0 1.2 6.2 1.1 5.4
20 0.01 0.17 0.01 0.15 0.10 0.14†
23† 0.03 0.17 0.04 0.17 0.01 0.16
36.3 51.6 0
19.2 9.7 20.0
44.5 38.7 80.0§
stment for age and gender. No significant differences for other comparisons were found. For mitralre E
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oxine r
and 9
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l Hype
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5 71
3 10
90.9
9.1
0
9 6.
2 0.
8 0.
33.3
33.3
33.3
ter adju
re. ‡Cross-sectional measures at 5-year follow-up. §p  0.08 compared with euthyroid category.
nt from baseline to 5-year follow-up; other abbreviations as in Table 2.
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ith TSH 10.0 mU/l.
To our knowledge, the authors (10) of only one previous
opulation-based prospective study directly examined the
elationship between subclinical hypothyroidism and HF
vents. They found that adults ages 70 to 79 years with
SH 7.0 mU/l had a greater risk of HF (HR: 2.88; 95%
I: 1.39 to 5.99) in multivariate analysis compared with
uthyroid participants, with a more pronounced risk in
hose with TSH 10.0 mU/l (HR: 3.10; 95% CI: 1.30 to
.39), and no increased risk in those with TSH 4.5 to 6.9
U/l. Possible explanations for the weaker point estimate
ound in CHS compared with the Health ABC (Health,
ging, and Body Composition) study include differences in
he study population that was mainly white in CHS (40%
ere black in Health ABC), younger mean age (72.6 vs.
4.7 years), different length of follow-up (12 years vs. 4
ears), no upper TSH cutoff in Health ABC analysis (1%
ith TSH 20.0 mU/l), and less precision as a result of
ower power in the Health ABC.
In the present study, the fact that HF risk was limited to
articipants with TSH 10.0 mU/l who were not taking
hyroxine, with a HF risk similar to the euthyroid group
nder thyroxine replacement, strengthens the case for a
otential causal relationship, which could only be defini-
ively proven by RCTs. Potential mechanisms for the
mpact of thyroid dysfunction on HF may be related to the
ffects of thyroid hormones on the heart (5,7), notably by
he regulation of genes coding for cardiac proteins (5). Overt
ypothyroidism also alters cardiovascular function (24).
For most echocardiographic measurements, we found no
ignificant differences for subclinical hypothyroidism or
yperthyroidism compared with euthyroidism, results that
re in contrast to several nonpopulation-based studies
6,25–27) but are consistent with other population-based
tudies (28,29). Several explanations exist for these discrep-
nt findings, including the age of the underlying study
opulation and the degree of subclinical thyroid dysfunction
8). All of these previous studies had insufficient sample
izes with subclinical hypothyroidism (n  8 to 66 as
ompared with 474 in the present study) to investigate
ifferent TSH cutoffs (7,28), and none linked abnormalities
n the surrogate echocardiographic markers with HF events
8). Indeed, our participants with subclinical hyperthy-
oidism demonstrated some differences in baseline echocar-
iographic measurements but no increase in HF events,
uggesting that these echocardiographic abnormalities, al-
hough statistically significant, do not result in HF. In our
ohort, those patients with TSH 10.0 mU/l had a greater
eak E velocity at baseline, an echocardiographic measure-
ent of diastolic function that was associated with incident
F in this cohort sample and previous CHS analysis (14).
he greater early diastolic filling velocity we found in
articipants with TSH 10.0 mU/l may reflect increased
eft atrial pressure and diastolic dysfunction from more
arked subclinical hypothyroidism. Some small RCTs have leen performed that have shown improvement in echocar-
iographic measures of cardiac function (30–32), support-
ng our findings of reduction of risk of HF after thyroxine
nitiation.
tudy limitations. Among limitations, our data may not be
eneralizable to younger age groups, and it has been
uggested that there may be age differences in the associa-
ions between subclinical thyroid dysfunction and adverse
utcomes (33). Thyroid function testing was performed at a
ingle point in time, which is a limitation of all published
bservational cohorts (10,11,34). Our power was limited in
hose with TSH 10.0 mU/l because this group was small.
ur echocardiographic findings could be affected by multi-
le comparisons and missing data for 5-year and incident
F echocardiograms; we could not definitively conclude on
he type of cardiac dysfunction (systolic or diastolic) in-
olved in those with TSH 10.0 mU/l, which needs to be
xplored in future studies.
These data have a number of strengths: the large,
opulation-based cohort of older adults, which was designed to
xamine cardiovascular risk factors; the mean 12-year follow-
p; the formal adjudication of HF events; the exclusion of
ndividuals who were taking thyroxine or other medications
hat could affect thyroid function testing; and the incorporation
f thyroxine use over time analytically (9). In addition, few
arge prospective studies have the availability of baseline and
ollow-up echocardiography data.
onclusions
ur data suggest that subclinical hypothyroidism with a
SH 10.0 mU/l represents a potentially modifiable risk
actor for HF in older adults but not subclinical hypothy-
oidism with moderate TSH levels (TSH 4.5 to 9.9 mU/l)
nd subclinical hyperthyroidism. Our study builds on the
revious study demonstrating increased HF risk in marked
ubclinical hypothyroidism (10), with additional mechanis-
ic support in our study from echocardiographic data and
nformation on reversibility of HF risk with thyroxine
eplacement. Our findings of a lack of HF risk in the high
roportions of older adults with less severe subclinical
ypothyroidism also are important because many patients
ith TSH levels of 4.5 to 9.9 mU/l are treated in clinical
ractice (35) without consistent evidence to support in-
reased risk without thyroxine replacement and improved
isk with replacement (1,3). This and previous studies have
ostly found no increased cardiovascular risk in subjects
ith TSH 10.0 mU/l (9,10,36), with some conflicting
ata (11). Moreover, approximately 20% of patients are
urrently overtreated by thyroxine replacement, with an
ncreased risk of subclinical hyperthyroidism that has been
ssociated with atrial fibrillation and increased fracture risk
3,37). In aggregate, our findings might help refine a
reatment threshold at which clinical benefit would be
xpected (8) and demonstrate a subpopulation at risk for a
ife-threatening condition. The authors of clinical trials
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ubclinical thyroid dysfunction and assess whether the risk
f HF might be ameliorated by thyroxine replacement in
ndividuals with TSH levels above 10.0 mU/l.
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